분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-04-23 13:58:30 , Hit : 2497
 Tales of Aptamer Selection: Astute Observation and Thoughtful Experimentation or Serendipity?

© 2014 TriLink BioTechnologies, Inc. | All Rights Reserved

Research Update


Selection methods for aptamers use large libraries of random oligonucleotides (~1 X 1015 oligomers).  The theory behind the use of these huge, non-discriminate libraries lies in probability – the probability that within each library is at least one candidate that targets your protein of interest. Thus, the number of molecules that are highly selective for other proteins is vast, many of which must be prime candidates for research, therapeutic or diagnostic tools. While researchers enter an experiment looking for an aptamer targeted to a specific protein, in a recent report, From Ugly Duckling to Swan: Unexpected Identification from Cell-SELEX of an Anti-Annexin A2 Aptamer Targeting Tumors, Frédéric Ducongé and colleagues show that through careful observation and thoughtful experimentation even a failed round of selection can lead to the discovery of a disease-relevant aptamer.  

Nucleic acid aptamers are short sequences of single-stranded RNA or DNA that target a desired molecule, similar to an antibody. However, aptamers contain superior qualities to antibodies because they are more stable, exhibit favorable toxicity profiles, have a simpler and more robust production process, are highly discriminate and can be engineered to contain various properties, such the use of 2′ Fluoro NTPs for nuclease resistance (Keefe and Cload, 2008). First described in 1990, the traditional selection process involved an iterative selection-amplification method aptly named ‘systematic evolution of ligands by exponential enrichment’ (SELEX) (Ellington and Szostak, 1990; Tuerk and Gold, 1990). Since then, alternative methodologies have been developed. One such method, Cell-SELEX, utilizes the same selection-enrichment process, but the target is within its cellular environment, thus containing a heterogeneous mixture of proteins and other cellular components (Morris et al., 1998). Recently, Cibiel et al. used the Cell-SELEX method to screen for an aptamer against human Endothelin Type-B Receptor (ETBR)(Cibiel et al., 2014), a G-coupled protein receptor that mediates vasodilation through the binding of Endothelin-1. Notably, Cell-SELEX allows for membrane proteins to retain their native conformation, essential when targeting receptors, and is useful to target cell-specific receptors and proteins. Important to Cell-SELEX, there must be a negative selection step against a cell type that does not express the desired target (Ohuchi, 2012).

Initially, the authors incubated a random RNA oligo library with wild-type (wt) CHO-K1 cells (for negative selection) and CHO-K1 cells transformed to stably overexpress ETBR (CHO-ETBR) to positively select for ETBR specific aptamers. After 15 rounds of selection and amplification, they found 26 sequences represented 1-7% of the total population and seven of those were found to have significantly higher binding than a scramble sequence when assayed against CHO-ETBR cells and MCR-7 cells, a cell line that naturally expresses the type A and type B endothelin receptors. All seven aptamers also bound to wt CHO cells, suggesting that none of these aptamers are specific for ETBR. Interestingly, three candidates failed to bind after pre-incubation of Endothelin-1. This suggests that while these may not specifically target the ETBR protein, they must interact closely with it. Competitive binding assays demonstrated that two of the aptamers, ACE4 and ACE26, target the same motif of an unknown membrane protein, with ACE4 having the highest binding affinity.

Despite the fact that none of the candidates passed the initial criteria (they bound to both CHO-ETBR and wt CHO-K1 cells), the authors concluded that ACE4 may be an attractive candidate to target cancer specific cells due to that fact that it exhibited 10 times higher binding affinity on MCF-7 cells (a well-studied breast cancer model) as compared to wt CHO-K1 cells. The authors next set out to determine the target protein of ACE4. Initial results showed that ACE4 binds preferentially to Annexin A2, and further studies determined it specifically targets the hetero-tetrameric form, AnxA2t. Interestingly, Annexin A2 had previously been reported to be increased in various cancer models. The authors went on to show that ACE4 efficiently and preferentially binds to several cancer cell lines in vitro. Furthermore, fluorescently-labeled ACE4 is able to be internalized within 30 minutes of incubation with MCF-7 cells. Finally, it was demonstrated that ACE4 binds to MCF-7 tumor xenografts in vivo using fluorescence diffuse optical tomography (fDOT).

In this report, the authors demonstrate that while they did not obtain an aptamer to the intended target, through thoughtful experimentation they found they had a specific and high affinity aptamer to a membrane protein upregulated in many cancers. While its usefulness as a diagnostic or therapeutic tool remains to be seen, the results are promising and they convincingly demonstrate that active investigation into undesirable candidates may result in exciting and relevant aptamers.  Whether considered the fruit of astute observation or simple serendipity, in the wise words of Louis Pasteur, “Fortune favors the prepared mind.”







867   실험쥐가 남성 연구자로부터 받는 스트레스?  이성욱 2014/05/02 2128
866   세계의 과학자들, 성인의 세포를 이용해 배아줄기세포를 만드는 데 잇달아 성공  이성욱 2014/04/30 1574
865   백신 개발을 위한 HIV의 취약 부위의 발견  이성욱 2014/04/30 1630
864   다운 증후군과 백혈병 사이의 연관성을 밝혀주는 연구 결과  이성욱 2014/04/24 2099
863   다시 뛰는 RNAi: 10억 달러 들여 신약 개발, 150가지 요법 임상시험  이성욱 2014/04/24 2791
862   Anti-viral regimen to treat adults with HCV awaits FDA approval  이성욱 2014/04/24 1439
  Tales of Aptamer Selection: Astute Observation and Thoughtful Experimentation or Serendipity?  이성욱 2014/04/23 2497
860   암 줄기세포의 항암제 저항성과의 연관성  이성욱 2014/04/23 2315
859   CTLA-4 항체의 항암 효과를 높이는 새로운 혼합치료  이성욱 2014/04/21 2102
858   난자와 정자의 결합을 가능하게 하는 단백질 발견  이성욱 2014/04/21 2068
857   HPV가 만든 인간 유전체의 고리가 암으로 진행  이성욱 2014/04/21 1907
856   First Patent Issued on CRISPR-Cas9  이성욱 2014/04/18 2007
855   왜 여성은 남성보다 더 알츠하이머 질환에 취약한가?  이성욱 2014/04/16 1898
854   트라우마의 추억 - 트라우마의 표지를 운반하는 정자의 miRNA  이성욱 2014/04/16 1924
853   Bristol-Myers hepatitis C treatment cures up to 90 pct -study  이성욱 2014/04/12 1602
852   Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene Therapy  이성욱 2014/04/11 1822
851   나쁜 환경의 스트레스가 텔로미어 길이 단축할까  이성욱 2014/04/11 2285
850   FDA grants priority review for ledipasvir/sofosbuvir  이성욱 2014/04/10 1917
849   일본 STAP 세포연구의 세포주 불일치 발견과 조사위원회의 과학적 위법행위 발표  이성욱 2014/04/03 2017
848   STAP 논문, 결국 62일 만에...  이성욱 2014/04/02 1658

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN